206 related articles for article (PubMed ID: 12820470)
1. The value of positron emission tomography in the follow-up for breast cancer.
Siggelkow W; Zimny M; Faridi A; Petzold K; Buell U; Rath W
Anticancer Res; 2003; 23(2C):1859-67. PubMed ID: 12820470
[TBL] [Abstract][Full Text] [Related]
2. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma.
Moon DH; Maddahi J; Silverman DH; Glaspy JA; Phelps ME; Hoh CK
J Nucl Med; 1998 Mar; 39(3):431-5. PubMed ID: 9529287
[TBL] [Abstract][Full Text] [Related]
3. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
4. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
[TBL] [Abstract][Full Text] [Related]
5. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers.
Suárez M; Pérez-Castejón MJ; Jiménez A; Domper M; Ruiz G; Montz R; Carreras JL
Q J Nucl Med; 2002 Jun; 46(2):113-21. PubMed ID: 12114874
[TBL] [Abstract][Full Text] [Related]
6. Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan.
Shen YY; Liang JA; Chen YK; Tsai CY; Kao CH
Hepatogastroenterology; 2006; 53(69):348-50. PubMed ID: 16795969
[TBL] [Abstract][Full Text] [Related]
7. 2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer.
Zimny M; Siggelkow W; Schröder W; Nowak B; Biemann S; Rath W; Buell U
Gynecol Oncol; 2001 Nov; 83(2):310-5. PubMed ID: 11606090
[TBL] [Abstract][Full Text] [Related]
8. [Diagnostic and therapeutic impact of 18F-FDG-PET/CT in patients with suspected breast cancer recurrence].
Palomar Muñoz A; García Vicente AM; Talavera Rubio MP; Pilkington Woll JP; Poblete García VM; Bellón Guardia ME; León Martín A; Cordero García JM; Soriano Castrejón A
Rev Esp Med Nucl; 2010; 29(3):100-8. PubMed ID: 20392542
[TBL] [Abstract][Full Text] [Related]
9. Value of 18fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma.
Bender H; Kirst J; Palmedo H; Schomburg A; Wagner U; Ruhlmann J; Biersack HJ
Anticancer Res; 1997; 17(3B):1687-92. PubMed ID: 9179219
[TBL] [Abstract][Full Text] [Related]
10. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.
Thrall MM; DeLoia JA; Gallion H; Avril N
Gynecol Oncol; 2007 Apr; 105(1):17-22. PubMed ID: 17208284
[TBL] [Abstract][Full Text] [Related]
11. 18-Fluorodeoxyglucose-positron emission tomography in inflammatory breast cancer.
Baslaim MM; Bakheet SM; Bakheet R; Ezzat A; El-Foudeh M; Tulbah A
World J Surg; 2003 Oct; 27(10):1099-104. PubMed ID: 12917770
[TBL] [Abstract][Full Text] [Related]
12. [18F]-Fluorodeoxyglucose positron emission tomography in patients with suspected recurrence of breast cancer.
Kamel EM; Wyss MT; Fehr MK; von Schulthess GK; Goerres GW
J Cancer Res Clin Oncol; 2003 Mar; 129(3):147-53. PubMed ID: 12712329
[TBL] [Abstract][Full Text] [Related]
13. Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: preliminary experience.
Hathaway PB; Mankoff DA; Maravilla KR; Austin-Seymour MM; Ellis GK; Gralow JR; Cortese AA; Hayes CE; Moe RE
Radiology; 1999 Mar; 210(3):807-14. PubMed ID: 10207485
[TBL] [Abstract][Full Text] [Related]
14. Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET.
Eubank WB; Mankoff DA; Vesselle HJ; Eary JF; Schubert EK; Dunnwald LK; Lindsley SK; Gralow JR; Austin-Seymour MM; Ellis GK; Livingston RB
Radiographics; 2002; 22(1):5-17. PubMed ID: 11796893
[TBL] [Abstract][Full Text] [Related]
15. Clinical impact of (18)F-FDG PET in management of patients with renal cell carcinoma.
Rodríguez Martínez de Llano S; Jiménez-Vicioso A; Mahmood S; Carreras-Delgado JL
Rev Esp Med Nucl; 2010; 29(1):12-9. PubMed ID: 20022140
[TBL] [Abstract][Full Text] [Related]
16. Fluorodeoxyglucose positron emission tomography for detection of recurrent or metastatic breast cancer.
Kim TS; Moon WK; Lee DS; Chung JK; Lee MC; Youn YK; Oh SK; Choe KJ; Noh DY
World J Surg; 2001 Jul; 25(7):829-34. PubMed ID: 11572019
[TBL] [Abstract][Full Text] [Related]
17. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer.
Crippa F; Agresti R; Seregni E; Greco M; Pascali C; Bogni A; Chiesa C; De Sanctis V; Delledonne V; Salvadori B; Leutner M; Bombardieri E
J Nucl Med; 1998 Jan; 39(1):4-8. PubMed ID: 9443729
[TBL] [Abstract][Full Text] [Related]
18. Detection of occult disease in breast cancer using fluorodeoxyglucose camera-based positron emission tomography.
Pecking AP; Mechelany-Corone C; Bertrand-Kermorgant F; Alberini JL; Floiras JL; Goupil A; Pichon MF
Clin Breast Cancer; 2001 Oct; 2(3):229-34. PubMed ID: 11899417
[TBL] [Abstract][Full Text] [Related]
19. PET imaging in breast cancer.
Bombardieri E; Crippa F
Q J Nucl Med; 2001 Sep; 45(3):245-56. PubMed ID: 11788817
[TBL] [Abstract][Full Text] [Related]
20. Value of fourth and subsequent post-therapy follow-up 18F-FDG PET/CT scans in patients with breast cancer.
Taghipour M; Sheikhbahaei S; Trahan TJ; Subramaniam RM
Nucl Med Commun; 2016 Jun; 37(6):602-8. PubMed ID: 27110955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
